TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00458497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holofiber fabric
Description: Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PET fabric
Description: Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
Study: NCT00931346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: emtricitabine/tenofovir disoproxil fumarate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03342300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Several efforts have been made to improve the toxicity profile of conventional anthracyclines, including the use of liposomal encapsulation technology,such as pegylated liposomal doxorubicin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pirarubicin
Description: Another effort has been made to improve the toxicity profile of conventional anthracyclines is the development of novel anthracycline analogs,such as pirarubicin.
Study: NCT02483052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RejuvenAir
Description: RejuvenAir
Study: NCT02718950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Description: Subjects will use liraglutide 3.0 mg for 2 weeks
Study: NCT02963961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Cognitive Training Battery
Description: Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
Study: NCT02189863

Intervention type: DEVICE
Group type: OTHER
Intervention: Comfilcon A MF
Description: Multifocal contact lenses worn in both eyes

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Contact lenses worn in both eyes per subject's habitual prescription

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual contact lenses
Description: Contact lenses worn in both eyes per subject's habitual prescription
Study: NCT04898998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Description: Surgical patients under general anesthesia were recruited from a medical center. Each patient was randomly assigned to the experimental group (TENS) or control group (routine care).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine care
Description: routine care
Study: NCT01339494

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine and citrulline supplementations
Description: Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Arginine and citrulline supplementations
Description: Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
Study: NCT02784652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
Study: NCT04301258

Intervention type: OTHER
Intervention: Articular cartilage repair
Description: Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
Study: NCT02784652

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 5 days/ week, 3 Gy \* 10-13 fractions or 4 Gy \* 5 fractions,
Study: NCT05943483

Intervention type: OTHER
Intervention: CCMQ questionnaire
Description: Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.
Study: NCT04301258

Intervention type: OTHER
Intervention: Articular cartilage repair
Description: Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.

Intervention type: OTHER
Intervention: Articular cartilage repair
Description: Patient reported outcomes will be collected on patients who have had a cartilage repair procedure using ProChondrix CR in the knee, hip, foot or ankle.
Study: NCT03980405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1- Control Diet
Description: Oral 5ASA+ Low Residue Diet for 6 weeks and Oral 5ASA+ Free Diet for 6 more weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2- UCD Diet
Description: Oral 5ASA+ UC Diet for 6 weeks and Oral 5ASA+ UC Diet Stage 2 for 6 more weeks
Study: NCT01807026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2886721

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04837469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fissure sealant application
Description: fissure sealants were placed after differnt adhesive strategies used

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fissure sealant application
Description: fissure sealants were placed after differnt adhesive strategies used
Study: NCT01391299

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
Study: NCT03909581

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic coronary arterial bypass
Description: is defined, for the purposes of this trial, as a planned off-pump minimally invasive (sternal-sparing), isolated LIMA-LAD revascularization (50 participants)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: will be performed using standard techniques at the discretion of the operator (50 participants)
Study: NCT02230579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 5mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 20mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 40mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 80mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 120mg
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match MMV390048
Description: Supplied as powder in bottle formulation for reconstitution pre-dose
Study: NCT02619708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersive Preoperative Experience
Description: The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
Study: NCT03116451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Foot Health Promoting Program
Description: An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
Study: NCT03702270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Penicillin Allergic Risk Stratification Best Practice Alert
Description: Providing best practice information on a patient's penicillin allergy risk and how to manage different levels of risk.
Study: NCT00827268

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: One-on-one treatment of reading difficulties
Description: Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
Study: NCT02584621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check Yourself App with Feedback
Study: NCT01874704

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comparison of biomarkers of stress
Study: NCT03046238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
Study: NCT02553603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone (GHRH)
Description: Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone (GHRH)
Description: Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone Releasing Hormone
Description: Placebo GHRH to be given once daily for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone Releasing Hormone
Description: Placebo GHRH to be given once daily for 10 weeks
Study: NCT02533960

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention.

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention.

Intervention type: OTHER
Intervention: not applicable (observational study)
Description: Observational study without study related intervention.
Study: NCT00613197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epanova
Description: 4g/day in divided doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epanova
Description: 4g/day in divided doses
Study: NCT00597844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: voice evaluation and fMRI
Description: will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: undergo voice evaluation and fMRI prior
Description: in approximately one month and six months
Study: NCT03865706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin Oral Suspension
Description: Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin Oral Suspension
Description: Inulin powder, derived from chicory root and re-suspended in 250cc water Dosage will be either 8g twice a day or 16g twice a day - dissolved in 250cc sterile water, given oral or via enteric tube

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Suspension
Description: 250cc sterile water alone, given twice daily a sweetener is added to the water to create identical flavor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Description: Standard of care treatment for infections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotics
Description: Standard of care treatment for infections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Broad-spectrum antibiotics
Description: Standard of care treatment for infections
Study: NCT03989908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfludic noodle
Description: In this intervention arm, subjects will be served with noodles made using microfludic technology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microfludic noodle
Description: In this intervention arm, subjects will be served with noodles made using microfludic technology.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control noodle
Description: In this intervention arm, subjects will be served with normal noodle.
Study: NCT04611464

Intervention type: DRUG
Intervention: Misoprostol
Description: Misoprostol is a PGE1 analog
Study: NCT02917863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Thyroxine (tablet, per os)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Thyroxine (oral drops, solution)
Study: NCT01878006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03424109

Intervention type: BEHAVIORAL
Intervention: healthcare service utilization in the six months following the ED visit
Description: The analysis of the effect of PRIM-ER on ED disposition using a generalized linear binomial model with random site level effects.
Study: NCT02202681

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OFDI Capsule
Description: Imaging of the duodenum with the OFDI capsule and system
Study: NCT00492921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT04591288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation protocol
Description: FES-assisted treadmill walking followed by a 12-week follow-up period. Subjects will train three times a week walking at a target speed corresponding to 60-80% of their age-predicted maximum heart rate. Each training session will consist of five six-minute walking bouts, with five-minute rest periods between bouts. Each treadmill bout consists of alternating one- minute intervals of FES on and FES off. For the last walking bout, the first three minutes will be FES-assisted on the treadmill and the last three minutes will be overground walking without FES assistance to promote carryover effects. Total walking time is 30 minutes and the entire training session lasts approximately 50 minutes.
Study: NCT01499862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tibion Bionic Leg
Description: A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
Study: NCT04447872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of injectable gonadotropins
Description: Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Timing of injectable gonadotropins
Description: Gonadotropins will with be started in the luteal phase or in follicular phase (preceded by Estradiol patches)
Study: NCT03191578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUTI®
Description: Administration of RUTI®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT03931343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance
Description: Thoracolumbar interfascial plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between multifidus and longissimus muscle with USG guidance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
Description: Erector spinae plane block: Bilateral 20 ml 0.25 % Bupivacaine with 2mg preservative free dexametasone and 5mcg/ml epinephrine injected between the erector spinae muscles and transverse process with USG guidance
Study: NCT03395132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fucicort® Lipid cream
Description: The active ingredient of Fucicort® Lipid cream are Fusidic acid and betamethasone. The pack size of Fucicort® Lipid cream is 15g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fucidin® cream
Description: The active ingredient of Fucidin® cream is Fusidic acid. The pack size of Fucidin® cream is 15g.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fucicort® Lipid cream vehicle
Description: The active ingredient of Fucicort® Lipid cream vehicle is the identical cream of Fucicort® Lipid cream but without the active ingredient. The pack size of Fucicort® Lipid cream vehicle is 15g.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone (Lianbang Beisong®) cream
Description: The active ingredient of betamethasone (Lianbang Beisong®) cream is Betamethasone hydrate. The pack size of betamethasone (Lianbang Beisong®) cream is 15g.
Study: NCT02866487

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
Study: NCT01268371

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Promus Element, Boston Scientific Corporation
Description: Everolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nobori, Terumo Corporation (Japan)
Description: Biolimus-eluting stent with biodegradable polymer
Study: NCT02217540

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard protocol
Description: Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard protocol
Description: Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Concept Mobilisation with Movement
Description: The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
Study: NCT01117792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: subcutaneous implantable defibrillator (S-ICD) system
Description: implantable defibrillator system
Study: NCT00521001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study: NCT01807702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C-Pyruvate 13C-lactate and dichloroacetate
Description: Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
Study: NCT00046891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba
Description: Patients will take 120 mg per day (60 mg BID)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take 1 tablet BID
Study: NCT04349293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Collection of a sample of tumor tissue and a sample of adjacent or counter lateral healthy tissue (if possible) from the surgical room

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Collection of a 30mL peripheral blood sample in heparin at several times: during surgical and medical treatment (before surgery, before the start of mAbs and after mAbs)
Study: NCT00286611

Intervention type: PROCEDURE
Intervention: Blood and salivary sampling of amifostine
Description: Sampling of blood and saliva to test for amifostine levels.